Novartis: new results in breast cancer
(CercleFinance.com) - On Friday, Novartis presented new Phase III follow-up data showing that Kisqali reduced disease recurrence in patients with certain forms of early breast cancer.
According to the Swiss pharmaceutical group's table, the three-year invasive disease-free survival (IDFS) rate was as high as 94% in certain types of breast cancer when Kisqali was combined with endocrine therapy.
The laboratory plans to report on these results today during a presentation at the annual congress of the European Society for Medical Oncology (ESMO).
Copyright (c) 2023 CercleFinance.com. All rights reserved.
According to the Swiss pharmaceutical group's table, the three-year invasive disease-free survival (IDFS) rate was as high as 94% in certain types of breast cancer when Kisqali was combined with endocrine therapy.
The laboratory plans to report on these results today during a presentation at the annual congress of the European Society for Medical Oncology (ESMO).
Copyright (c) 2023 CercleFinance.com. All rights reserved.